Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $387

Morgan Stanley maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $375 to $387.

Benzinga · 11/06/2019 14:08

Morgan Stanley maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $375 to $387.